Controlling The Haematopoietic System To Treat Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$2,163,220.00
Summary
The Murphy laboratory studies how the body makes blood. In people with heart disease too much blood is made that quickens the progression of heart disease. Slowing the production of blood back to normal seems to slow this progression. In this project, they will discover how and why more blood is made and ways to limit this.
Deciphering Mechanisms Underlying Breast Cancer To Improve Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$3,314,215.00
Summary
Breast cancer is a highly heterogeneous disease. Patients are often treated in a ‘one size fits all’ approach, but response to therapy remains disparate. To more effectively personalise therapy, there is a pressing need to define the precise cell types and initiating genetic events that give rise to breast cancer. This application is centred on understanding mechanisms of breast cancer initiation and progression, with the potential of identifying new prognostic markers and therapeutic targets.
Natural killer (NK) cell posses the ability to detect and kill transformed or stressed cells such as tumour cells. My recent data show that NK cells are required for efficient immunotherapy responses by enhancing the global immune response to cancer and preventing tumour cells from metastasising to vital organs. I propose to identify novel pathways and develop new therapeutic approaches to exploit NK cell anti-tumor function and improve cancer immunotherapy response rates in patients.
Molecular Diagnosis And Therapy Of Autoimmune Disease Using Translational And Reverse Translational Approaches
Funder
National Health and Medical Research Council
Funding Amount
$2,331,372.00
Summary
We plan to translate our recent discoveries on human gene variants and molecules produced by immune cells (follicular T cells) into effective therapies for autoimmune diseases. This will involve understanding the mechanisms by which the genes and molecules regulate immune tolerance, stratifying patients with autoimmune disease using newly identified biomarkers, trialling existing biologicals according to affected molecular pathway, and taking novel targets through to commercialisation.
Precision Prevention Of Colorectal Cancer: Understanding Tumourigenesis In High Risk People To Optimise Prevention
Funder
National Health and Medical Research Council
Funding Amount
$1,562,250.00
Summary
Bowel cancer, Australia’s second most common cause of cancer death, is one of the most preventable cancers. We know some people have a high risk because they carry changes in their DNA, or they have many pre-cancerous growths (polyps). Bowel cancer is increasing in young people, before 50 years of age, with no known reason. If we can identify people who have a high risk and understand how and why it develops in young Australians, we can prevent these cancers.
Targeting Epigenetic Mechanisms Of Immune Evasion In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$1,425,280.00
Summary
Proteins called MHC class I and II on the surface of cancer cells act as sensors that allow the immune system to recognise cancer cells as abnormal and destroy them. However, cancer cells have developed ways to hide from the immune system by silencing MHC class I and II. This project aims to identify ways to overcome this silencing and restore MHC class I and II to the surface of the cancer cells, allowing them to be treated with therapies that activate immune cells to eradicate the tumour.
Realising The World Health Organisation Targets For Elimination Of Cervical Cancer As A Public Health Problem: Effective Implementation And Scale-up Of HPV Vaccination And Cervical Screening In Australia, Regionally, And Globally
Funder
National Health and Medical Research Council
Funding Amount
$2,125,000.00
Summary
This fellowship focuses on improving cancer screening, particularly the implementation of HPV vaccination and cervical screening. CI Canfell will pursue an Australian, regional and global health agenda towards the elimination of cervical cancer. Her work is supporting the successful implementation of the new cervical screening program in Australia, provides crucial support to other countries in the region, and is directly informing the WHO global elimination strategy.
An In Vitro Pipeline For Liquid Biopsy Biomarkers For Cancer Diagnosis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$3,764,215.00
Summary
A droplet of blood contains information whether a person has cancer, the stage of the cancer and how their response to treatment. The proposed research will employ ultrasensitive detection technologies to analyse so-called biomarkers released from cancer cells. We will use lab-based models of cancer, generated with a 3D bioprinter, to learn what biomarkers tell us about cancer type and response to drugs. This knowledge is urgently needed for early cancer detection and better cancer treatment.
Understanding Immune Responses To Severe Influenza Virus Infection And Vaccination In Humans
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
During influenza virus infection, people acquire robust and long-lasting immunity. However, current influenza vaccines elicit only transient immunity. I will define optimal responses in different immune cell types after natural infection versus vaccination; understand why some people fail to generate protective antibodies to the vaccine; and identify key biomarkers aimed at reducing influenza disease impact in high risk groups. This work will improve future influenza vaccination regimens.
Understanding Immunity To Influenza B Viruses For A Rationally Designed Universal Vaccine
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Influenza B viruses (IBV) circulate annually and are particularly prevalent and severe in children. However, IBV remain largely understudied. Our immune system provides protection against IBV via a variety of mechanisms. This study will characterize the immunity to IBV and dissect host-virus interactions which provide protection from IBV infection. This project will inform the rational design of novel vaccines eliciting universal immunity to IBV, with an ultimate goal of controlling IBV.